KOSDAQBiotech & Pharma204840

GL Pharm Tech

₩3,115▼ 1.74%2026-11-18 close
Market Cap
₩48.3B
Turnover
₩87,846,440
Volume
30K
Shares out.
15.5M
PER
—
PBR
2.6×
EPS
-₩17
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Improved-drug portfolio holds profit; margin stability is the test

GL Pharm Tech swung to a full-year operating profit in 2025 after shifting toward improved drugs, but 3Q 2026 operating profit fell and net income attributable to controlling shareholders turned to a loss, so profit stability is the next thing to watch.

  1. 1

    2025 revenue rose 35.4% to KRW 35.3 billion, and operating profit of KRW 268 million replaced the prior year's operating loss.

  2. 2

    The lineup now spans several improved drugs and a first-generic product, with Lobaelzet and Telmielthan in launch preparation.

  3. 3

    Recoflavone, a dry-eye drug, received approval in September 2026, but reports differ on whether the launch comes in December 2026 or in the second half of 2027.

  4. 4

    3Q 2026 operating profit was KRW 137 million, down 40.7% from the prior quarter, and net income attributable to controlling shareholders swung to a loss of KRW 25.4 million.

  5. 5

    The debt ratio (total liabilities ÷ total equity) was 145.1% at end-2025, and operating cash flow was negative in each year from 2022 through 2025.

02

Business structure

GL Pharm Tech is a pharmaceutical company that builds its prescription drug portfolio around improved drugs and first-generic products. It absorbed its subsidiary GL Pharma by merger in summer 2026, bringing R&D, regulatory approval, manufacturing and sales under one corporate entity.

Before the merger, in the first half of 2026, the R&D and sales-marketing segment booked KRW 6.42 billion in revenue and the manufacturing and sales segment of the subsidiary booked KRW 14.42 billion; after eliminating KRW 1.70 billion of intra-group transactions, consolidated revenue was KRW 19.14 billion.

The manufacturing and sales segment accounted for a majority of combined segment revenue.

Key products are Riliel ODT (pregabalin, for neuropathic pain, launched May 2026), Proenza soft capsules (a first generic of Xtandi for prostate cancer, launched June 2026), Telmo-tablet line Teraelle for benign prostatic hyperplasia (a 2 mg strength added in September 2026), and Pitaelle ODT (pitavastatin, launched October 2026).

Some products are distributed through a partner, and the company has several co-development and licensing deals, including a sales agreement for Cabalin CR with HK inno.N. Its strategy rests on orally disintegrating tablets that can be taken without water.

Its dry-eye drug Recoflavone received domestic approval in September 2026, and the company holds rights in China, Japan and Europe, though no agreements there had been reported as signed.

Compared with larger listed pharma companies, it is smaller in scale and relies on licensing with large domestic partners to expand sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.5B₩300M2.6%
2025Q4₩9.5B-₩300M−3.1%
2026Q1₩9.4B₩34,628,4750.4%
2026Q2₩9.7B₩200M2.4%
2026Q3₩11.4B₩100M1.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16.7B-₩3.3B-₩800M−19.5%−4.9%153.9%
2023₩26B-₩3.2B-₩3.7B−12.4%−30.5%224.6%
2024₩26B-₩1.8B-₩2.3B−6.8%−11.9%115.8%
2025₩35.3B₩300M₩12,489,1920.8%0.1%145.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue rose from KRW 16.7 billion in 2022 to KRW 26 billion in 2023 (up 55.6%), then was essentially flat at KRW 26 billion in 2024 (up 0.1%). The KRW 35.3 billion recorded in 2025 was up 35.4% and was the largest year in the 2022–2025 period. Media also reported 2025 revenue as a record.

Operating losses of KRW 3.25 billion (2022), KRW 3.23 billion (2023) and KRW 1.77 billion (2024) gave way to an operating profit of KRW 268 million in 2025. The operating margin moved from -19.5%, -12.4% and -6.8% to 0.8% in 2025.

Net loss attributable to controlling shareholders widened to KRW 3.75 billion in 2023 before narrowing to KRW 2.34 billion in 2024, and turned to a profit of KRW 12.49 million in 2025. Net income including non-controlling interests for 2025 was also KRW 12.49 million.

The company attributed the 2025 improvement to a wider sales network, growth in core products, new launches and distribution diversification through contract sales for ETC products. Cost control and production efficiency also contributed.

By quarter, revenue was KRW 9.53 billion in 3Q 2025 and KRW 9.53 billion in 4Q 2025, dipped to KRW 9.43 billion in 1Q 2026, then rose to KRW 9.7 billion in 2Q and KRW 11.4 billion in 3Q 2026, up 17.8% quarter on quarter and 19.8% year on year.

Operating profit went from KRW 253 million in 3Q 2025 to an operating loss of KRW 294 million in 4Q 2025, recovered to KRW 34.63 million in 1Q 2026 and KRW 231 million in 2Q, then fell to KRW 137 million in 3Q 2026, down 40.7% quarter on quarter and 45.8% year on year.

Net income attributable to controlling shareholders was a profit in 2Q 2026 and a loss of KRW 25.4 million in 3Q 2026. The four quarters from 4Q 2025 to 3Q 2026 add up to a net loss attributable to controlling shareholders of KRW 265 million.

For the first half of 2026, revenue grew 18.1% while operating profit fell 14.3%, and an analysis attributed the gap to insufficient cost control. R&D spending in the first half was KRW 1.08 billion, or 5.64% of revenue. The merger had no financial effect on consolidated statements.

05

Industry analysis

In Korea's prescription drug market, improved drugs and first generics differentiate existing ingredients through formulation or strength changes. GL Pharm Tech is widening its prescription portfolio with a series of first-generic and higher-strength products.

The lipid-lowering combination market reached about KRW 723.6 billion in prescriptions in 2024 on the Yuster basis, while the company describes its Lobaelzet launch as targeting a domestic combination market of about KRW 800 billion; the two figures use different bases and are not directly comparable.

The domestic dry-eye treatment market is reported at about KRW 500 billion, and the global market is estimated at about KRW 6.5 trillion. Industry observers view unmet need as large, since only about 10% of diagnosed patients use prescription drugs and failure rates of existing treatments can reach 50%.

In the cycle, the company is in a phase of expanding improved-drug launches, while its new drug must clear pricing negotiations before generating sales, with a domestic launch reported for the second half of 2027.

Compared with large listed pharma companies such as Hanmi Pharm and Yuhan, the company is much smaller in revenue and research infrastructure. Recoflavone was co-developed with a partner, and some experts see technology-export talks for North American and European markets accelerating after approval.

Separately, a combination product for hypertension faces possible market reshaping if later entrants gain traction.

06

Outlook

The company has said it aims to launch at least five new pharmaceutical products in 2026 and is focusing on R&D and approval procedures. Riliel launched in May 2026, Proenza in June and Pitaelle in October. Reports differ on Lobaelzet: one points to a December 2026 launch, while another gives January 2027.

Telmielthan, a hypertension combination, is being prepared for market supply in January 2027.

Recoflavone received approval in September 2026, and reports conflict on timing: one says a launch in December 2026, another says the company is preparing for a 2027 launch, and a further report puts the domestic launch in the second half of 2027 after pricing negotiations.

The company's market target is a share of about 10% of the domestic market within several years. The company holds rights in China, Japan and Europe and is reviewing overseas moves, but no such agreements had been reported as signed.

After the merger, integrating R&D, manufacturing and sales is intended to speed decisions and strengthen cost competitiveness. The W2505 phase 3 trial is expected to end in August 2028.

The 2026 annual report, the next regular filing, will show how much the new products contributed to annual revenue and the operating margin.

07

Valuation

PER
—
PBR
2.6×
ROE
-1.3%
EPS
-₩17
BPS
₩1,281
Dividend per share
₩0

Because the last four quarters combined show net losses attributable to controlling shareholders, the price-to-earnings ratio is not calculated. The price-to-book ratio is well above 1x, meaning the shares trade at a premium to net assets at end-2025.

The dividend yield sits below the industry average, so dividends play a limited role in valuation.

Quarterly profit has not been stable, with operating profit of KRW 137 million and a net loss attributable to controlling shareholders of KRW 25.4 million in 3Q 2026, which makes earnings-based multiple comparisons difficult.

Profit has moved from loss to profit in 2025 and recovery is visible, but quarterly swings are large, so a trend cannot yet be confirmed. Media reported that expectations for the Recoflavone approval were priced in beforehand, and the shares fell after approval was granted.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Wider product lineup and new launches

Riliel, Proenza, Teraelle and Pitaelle are on the market, and Lobaelzet is in launch preparation. A hypertension combination was reported to have received approval in July 2026. A broader product base supports revenue diversification. The company has set a target of at least five new launches in 2026.

Recoflavone approval as a medium-term anchor

Recoflavone received approval in September 2026 as the 44th new drug in Korea. The domestic dry-eye market is reported at about KRW 500 billion, and the company aims for roughly 10% share within several years. It holds rights in China, Japan and Europe, which leaves room for overseas partnerships.

Post-turnaround structural change

Operating profit turned positive for full-year 2025, and quarterly operating profit stayed positive in 1Q through 3Q 2026. Merging the subsidiary into one entity is described as reducing duplicate management costs. Stabilized cost of sales has been cited as a margin factor.

09

Bear factors

Volatile profitability

3Q 2026 operating profit was KRW 137 million, down 40.7% from the prior quarter, and the quarter swung to a net loss attributable to controlling shareholders. The net loss attributable to controlling shareholders also persists when the latest four quarters are added together.

First-half revenue rose 18.1% while operating profit fell 14.3%. Revenue growth has not yet translated into steady profit.

Timing uncertainty for Recoflavone sales

Reports conflict on whether Recoflavone launches in December 2026 or in the second half of 2027. A pricing negotiation is required before domestic launch, and some commentators said approval expectations had already been priced in. Sales will take time to show up, so the medium-term thesis will take longer to confirm in earnings.

Balance sheet and cash flow burden

At end-2025, total liabilities were KRW 28.9 billion and total equity KRW 19.9 billion, a debt ratio of 145.1%. Operating cash flow was negative in each of the four years from 2022 through 2025. The debt ratio was 224.6% in 2023 and 115.8% in 2024. Continuous R&D spending adds to cash pressure.

10

Risk factors

Regulation, pricing and approval timing

Recoflavone needs a pricing agreement before domestic launch. Reports give different launch dates for Lobaelzet and Telmielthan. Any delay pushes back the point at which these products contribute revenue, and the pricing outcome will affect whether the share target is reachable.

Product competition and later entrants

Proenza entered as a first generic, and later generics could follow. Combination-drug markets already have several products, so share depends on prescription wins. Parts of sales rely on external distribution partners, and results depend on their capacity.

Merger execution and ownership

The merger combined the subsidiary into one organization, but whether integration and cost cuts translate into profit gains still needs confirmation. The largest shareholder holds 29.77%, and its change of control has shaped the strategy. First-half R&D spending was KRW 1.08 billion, or 5.64% of revenue.

11

What to watch next

  1. December 2026

    Whether Recoflavone launches as reported. One report says December 2026, while others point to 2027 preparation and a second-half 2027 launch, so actual launch and pricing listing are the first checks.

  2. December 2026 to January 2027

    Lobaelzet ODT launch. Reports differ on timing, and early prescription response will show how the product settles in the lipid-lowering combination market.

  3. January 2027

    Telmielthan market supply, which will show whether a hypertension product is added to the lineup.

  4. By March 31, 2027

    Filing of the 2026 annual report, the next regular disclosure, which will confirm full-year 2026 revenue, operating profit and operating cash flow.

  5. Second half of 2027

    Domestic launch of Recoflavone after pricing negotiations, which will show when sales begin and progress toward the roughly 10% share target.

12

Overall view

GL Pharm Tech shifted toward improved drugs and recorded a full-year operating profit in 2025 with revenue up 35.4%. Revenue rose in each quarter from 1Q through 3Q 2026, and operating profit stayed positive in every quarter from 1Q 2026.

However, 3Q 2026 operating profit fell 40.7% quarter on quarter, and the quarter swung to a net loss attributable to controlling shareholders. The debt ratio of 145.1% at end-2025 and negative operating cash flow in each year from 2022 through 2025 remain burdens.

The dry-eye drug Recoflavone received approval in September 2026, but reports differ on whether its launch falls in December 2026 or in the second half of 2027. Launch timing, pricing outcomes and cost structure after the merger are the next points to confirm.

The key test is whether revenue growth and profit stability move together, which can be checked in the 2026 annual report and later quarterly filings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. fnnews.com
  2. dailypharm.com
  3. dailypharm.com
  4. pharmnews.com
  5. dailypharm.com
  6. dailypharm.com
  7. dailypharm.com
  8. pharm.edaily.co.kr
  9. supple.kr
  10. biobookmedia.com
  11. glpt.co.kr
  12. mt.co.kr
  13. m.news.nate.com
  14. mt.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis